Search | Clinical Trials Finder

Conditions: Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions: Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Bardstown, Kentucky • Woburn, Massachusetts • Niles, Michigan + 1 more

Conditions: Prevention of Meningococcal Disease
Interventions: MenACWY-CRM Vaccine, MenACWY-PS Vaccine; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 12 Months to 10 Years
Enrollment: 910 participants
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Oakland, California

Conditions: Meningococcal Disease, Infections, Meningococcal
Interventions: Meningococcal quadrivalent CRM-197 conjugate vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 2 Months to 23 Months
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Meningococcal Meningitis, Meningococcal Infections
Interventions: meningococcal meningitis conjugate vaccine, quadrivalent; Biological
Lead sponsor: JN-International Medical Corporation; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Hanford, California

Conditions: Meningococcal Disease
Interventions: MenABCWY+OMV, MenABCWY+¼OMV, Placebo; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 194 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 8
States / cities: Birmingham, Alabama • Madera, California • Paramount, California + 5 more

Conditions: Meningitis, Meningococcal, Serogroup B
Interventions: rLP2086; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Adolescent Health Services, Immunization
Interventions: Assessment , Feedback, Incentives, and eXchange Program; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: Not listed
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Raleigh, North Carolina

Conditions: Meningitis, Meningococcal
Interventions: MenABCWY vaccine, Placebo, MenACWY vaccine, MenB vaccine; Combination Product · Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 15 Years to 25 Years
Enrollment: 1,250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 48
States / cities: Jonesboro, Arkansas • Banning, California • Chula Vista, California + 42 more

Conditions: Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 56 Years and older
Enrollment: 907 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 35
States / cities: Chandler, Arizona • Anaheim, California • San Diego, California + 28 more

Conditions: Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions: Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide, Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 56 Years and older
Enrollment: 139 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 6
States / cities: Scottsdale, Arizona • Bardstown, Kentucky • Albuquerque, New Mexico + 3 more

Conditions: Meningococcal Infections
Interventions: MenACWY-CRM + MMRV, MMRV, MenACWY-CRM; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 7 Months to 1 Year
Enrollment: 1,630 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 90
States / cities: Birmingham, Alabama • Dothan, Alabama • Greenville, Alabama + 69 more

Conditions: Infections, Meningococcal
Interventions: Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Prevnar13, Pediarix, Hiberix, Rotarix, M-M-R II, Varivax, Placebo (saline water), Prevnar 20; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Weeks to 12 Weeks
Enrollment: 1,196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 56
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 47 more

Conditions: Meningitis, Meningococcal
Interventions: rLP2086 vaccine or control; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Vaccine Preventable Diseases, Meningococcal Disease, Human Papillomavirus, Pertussis, Influenza
Interventions: Point-of-Care Prompt; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 11 Years to 18 Years
Enrollment: 7,040 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 22
States / cities: Little Rock, Arkansas • Wilmington, Delaware • Gainesville, Florida + 12 more

Conditions: Meningitis, Meningococcal Disease
Interventions: None administered in this study; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: Not listed
Enrollment: 62,626 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Oakland, California

Conditions: Meningitis, Meningococcal Infection
Interventions: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 15 Years to 23 Years
Enrollment: 145 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 8
States / cities: Atlanta, Georgia • Marietta, Georgia • Woburn, Massachusetts + 5 more

Conditions: Healthy Volunteers (Meningococcal Infection)
Interventions: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine), Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®), Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine, Pneumococcal 13-valent Conjugate Vaccine, Rotavirus Vaccine, Hepatitis B Vaccine, Measles, Mumps, and Rubella Virus Vaccine, Varicella Virus Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 42 Days to 89 Days
Enrollment: 2,797 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 67
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 56 more

Conditions: Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions: GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine, ActHIB, Pediarix, Prevnar, Menomune; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Weeks to 15 Months
Enrollment: 756 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 27
States / cities: Little Rock, Arkansas • Fountain Valley, California • Centennial, Colorado + 19 more

Conditions: Meningococcal Infection
Interventions: blood sampling, bivalent rLP2086; Procedure · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 698 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 36
States / cities: Chandler, Arizona • Huntington Beach, California • Paramount, California + 25 more

Conditions: Meningitis, Meningococcal Infection
Interventions: Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 9 Months to 23 Months
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Oakland, California

Conditions: Meningococcal Meningitis
Interventions: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 37 Months to 63 Months
Enrollment: 433 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 19
States / cities: Birmingham, Alabama • Downey, California • Oakland, California + 15 more

Conditions: Meningitis, Meningococcemia, Pertussis, Tetanus, Diphtheria
Interventions: T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj., Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj., Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 11 Years to 17 Years
Enrollment: 1,345 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 20
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Boulder, Colorado + 17 more

Conditions: Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine, ActHIB, PedvaxHIB, Pediarix, Prevnar, M-M-R II, Varivax; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Weeks to 15 Months
Enrollment: 4,441 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 88
States / cities: Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 76 more

Conditions: Guillain-Barre Syndrome
Interventions: Not listed
Lead sponsor: Harvard Pilgrim Health Care; Other
Eligibility: 11 Years to 21 Years
Enrollment: 6,000,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 6
States / cities: Wilmington, Delaware • Honolulu, Hawaii • Boston, Massachusetts + 3 more

Search by objective public record fields.

Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier

Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children

Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study

Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis

Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)

Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age

Examining Adolescent Assessment, Feedback, Incentive, and Exchange (AFIX) in North Carolina

Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older

Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination

Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults

Testing the Use of Prompts to Increase Adolescent Immunization Rates

Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine

Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®

Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine

Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose

Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children

Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

Safety Study of GBS Following Menactra Meningococcal Vaccination